The drug candidate demonstrated statistically significant reductions in AHI and improvements in oxygenation, coupled with positive patient-reported outcomes.| Sleep Review
Avadel Pharmaceuticals has licensed valiloxybate from XWPharma Ltd.| Sleep Review
Alkermes’ alixorexton met primary and key secondary endpoints in a phase 2 trial for narcolepsy type 1, showing dose-dependent improvements.| Sleep Review
Takeda’s investigational orexin-2 receptor agonist oveporexton met all endpoints in two phase 3 trials for narcolepsy type 1.| Sleep Review
